This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheung, A. M. Y. Articles by Mak, T. W. Search for Related Content PubMed PubMed Citation Articles by Cheung, A. M. Y. Articles by Mak, T. W.

Brca2 Deficiency Does Not Impair Mammary Epithelium Development but Promotes Mammary Adenocarcinoma Formation in p53^+/- Mutant Mice

¹ Advanced Medical Discovery Institute, Toronto, Ontario, Canada; ² Ontario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; ³ Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska; and ⁴ Laboratory of Genetics and Physiology, National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland

Brca2 is an important tumor suppressor associated with susceptibility to breast cancer. Although increasing evidence indicates that the primary function of Brca2 is to facilitate the repair of DNA damage via the homologous recombination pathway, how Brca2 prevents breast cancer is largely unknown. To study the role of Brca2 specifically in mammary epithelium development, we crossed mice bearing the conditionally deficient allele Brca2^flox9–10 to mouse mammary tumor virus- or whey acidic protein-Cre transgenic lines. Analysis of these animals showed that Brca2 is not required for epithelial expansion in mammary glands of pregnant mice. In addition, examination of mammary gland involution revealed normal kinetics of mammary alveolar cell apoptosis after weaning of litters. Nevertheless, Brca2-deficient mice developed mammary adenocarcinomas after a long latency (average, 1.6 years). Detailed histopathological analysis of four of these tumors demonstrated that three of them showed abnormal p53 protein expression. A mutation in the p53 gene was detected in one case. Moreover, homozygosity versus heterozygosity for the Brca2 mutation heavily skewed the tumor spectrum toward mammary adenocarcinoma development in p53^+/- mice. Our data indicate that Brca2 is not essential for mammary epithelium development but that Brca2 deficiency and down-regulated p53 expression can work jointly to promote mammary tumorigenesis.

This article has been cited by other articles:

				S. G. Kuznetsov, D. C. Haines, B. K. Martin, and S. K. Sharan Loss of Rad51c Leads to Embryonic Lethality and Modulation of Trp53-Dependent Tumorigenesis in Mice Cancer Res., February 1, 2009; 69(3): 863 - 872. [Abstract] [Full Text] [PDF]

				K. A. McAllister, C. D. Houle, J. Malphurs, T. Ward, N. K. Collins, W. Gersch, L. Wharey, J. C. Seely, L. Betz, L. M. Bennett, et al. Spontaneous and Irradiation-Induced Tumor Susceptibility in Brca2 Germline Mutant Mice and Cooperative Effects with a p53 Germline Mutation Toxicol Pathol, February 1, 2006; 34(2): 187 - 198. [Abstract] [Full Text] [PDF]